GALMED PHARMACEUTICALS LTD (GLMD) Stock Price & Overview
NASDAQ:GLMD • IL0011313900
The current stock price of GLMD is 0.64 USD. Today GLMD is up by 1.59%. In the past month the price decreased by -5.77%. In the past year, price decreased by -63.4%.
GLMD Key Statistics
- Market Cap
- 4.211M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.60
- Dividend Yield
- N/A
GLMD Stock Performance
GLMD Stock Chart
GLMD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to GLMD. When comparing the yearly performance of all stocks, GLMD is a bad performer in the overall market: 95.27% of all stocks are doing better.
GLMD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLMD. GLMD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GLMD Earnings
GLMD Forecast & Estimates
GLMD Groups
Sector & Classification
GLMD Financial Highlights
Over the last trailing twelve months GLMD reported a non-GAAP Earnings per Share(EPS) of -3.6. The EPS increased by 85.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.31% | ||
| ROE | -45.52% | ||
| Debt/Equity | 0 |
GLMD Ownership
GLMD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.24 | 402.577B | ||
| AMGN | AMGEN INC | 16.21 | 203.574B | ||
| GILD | GILEAD SCIENCES INC | 16.44 | 181.247B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.68 | 125.079B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.14 | 81.897B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.96 | 42.495B | ||
| INSM | INSMED INC | N/A | 30.048B | ||
| BIIB | BIOGEN INC | 11.53 | 27.955B | ||
| NTRA | NATERA INC | N/A | 27.865B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.15 | 23.875B | ||
| MRNA | MODERNA INC | N/A | 22.105B | ||
| EXAS | EXACT SCIENCES CORP | 339.85 | 19.738B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.736B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLMD
Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
Company Info
IPO: 2014-03-13
GALMED PHARMACEUTICALS LTD
16 Tiomkin Street
TEL AVIV-YAFO 6578317 IL
CEO: Allen Baharaff
Employees: 3
Phone: 97236938448
GALMED PHARMACEUTICALS LTD / GLMD FAQ
Can you describe the business of GALMED PHARMACEUTICALS LTD?
Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). The firm is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The firm's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The firm's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
What is the stock price of GALMED PHARMACEUTICALS LTD today?
The current stock price of GLMD is 0.64 USD. The price increased by 1.59% in the last trading session.
Does GALMED PHARMACEUTICALS LTD pay dividends?
GLMD does not pay a dividend.
What is the ChartMill rating of GALMED PHARMACEUTICALS LTD stock?
GLMD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for GALMED PHARMACEUTICALS LTD?
GALMED PHARMACEUTICALS LTD (GLMD) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of GALMED PHARMACEUTICALS LTD (GLMD)?
GALMED PHARMACEUTICALS LTD (GLMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.6).
Can you provide the market cap for GALMED PHARMACEUTICALS LTD?
GALMED PHARMACEUTICALS LTD (GLMD) has a market capitalization of 4.21M USD. This makes GLMD a Nano Cap stock.